Angiotensin Converting Enzyme Inhibitors and Periprocedural Myocardial Infarction

Angiotensin Converting Enzyme Inhibitor Therapy and Periprocedural Myocardial Infarction in Patients With Metabolic Syndrome

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02054390

Enrollment

459

Registered

2014-02-04

Start date

2014-02-28

Completion date

2014-06-30

Last updated

2014-06-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary Artery Disease, Metabolic Syndrome

Keywords

Angiotensin converting enzyme inhibitor, inflammation, metabolic syndrome, myonecrosis, percutaneous coronary intervention, periprocedural myocardial injury

Brief summary

Metabolic syndrome (MS) has been reported as a risk for cardiovascular events. The aim of the present cohort study is to investigate whether ACEi therapy reduces the rate of periprocedural myocardial injury (PPMI) after elective percutaneous coronary intervention (PCI) among patients with metabolic syndrome.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 80 Years

Healthy volunteers

Inclusion criteria

1. metabolic syndrome 2. elective percutaneous coronary intervention with angiographically successful stent implantation

Exclusion criteria

1. acute coronary events 2. renal failure 3. needed the use of IV glycoprotein IIb/IIIa receptor inhibitors were excluded 4. left main coronary artery disease 5. chronic total occlusion 6. high levels of baseline CKMB or troponin 7. any contraindication of aspirin, clopidogrel or ACEi treatment

Design outcomes

Primary

Measure	Time frame	Description
Periprocedural myocardial injury (MI)	24 hours after (percutaneous coroary intervention) PCI	Periprocedural MI was defined as cardiac Troponin I release \[5 times ULN\] 24 hours after percutaneous coronary intervention

Secondary

Measure	Time frame	Description
Periprocedural myonecrosis	24 hours after PCI	Peri-procedural myonecrosis was defined as troponin I release of \>1×ULN 24 hours after the intervention.

Other

Measure	Time frame	Description
inflammatory marker	24 hours after PCI	high sensitive C-reactive protein measurement 24 hours after PCI

Countries

Turkey (Türkiye)

Outcome results